Modality
siRNA
MOA
PD-1i
Target
IL-17A
Pathway
Complement
SLE
Development Pipeline
Preclinical
May 2020
→ Jun 2031
PreclinicalCurrent
NCT05060876
1,717 pts·SLE
2020-05→2031-06·Completed
1,717 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-06-025.2y awayInterim· SLE
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
Preclinical
Complet…
Catalysts
Interim
2031-06-02 · 5.2y away
SLE
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05060876 | Preclinical | SLE | Completed | 1717 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| RVM-7089 | Revolution Medicines | Phase 3 | IL-17A | |
| Adagrarapivir | Ideaya Bio | Phase 1/2 | IL-17A | |
| ZYM-2450 | Zymeworks | Phase 2 | GLP-1R | |
| Polazanubrutinib | Tango Ther | Phase 1 | IL-17A |